A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.
about
A synthetic adenylation-domain-based tRNA-aminoacylation catalystDrug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know.Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimusYin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling.Current and future immunosuppressive strategies in renal transplantation.Therapeutic monitoring of immunosuppressant drugs. Where are we?Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.Clinical application of sirolimus in renal transplantation: an update.Sirolimus: its role in nephrology.Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.Nanomedicines in renal transplant rejection--focus on sirolimusLearning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis.The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.Drug choices in autoimmune hepatitis: part B--Nonsteroids.Antivirulence activity of azithromycin in Pseudomonas aeruginosaThe evaluate and compare the effects of the Tacrolimus and Sirolimus on the intestinal system using an intestinal cell culture model.Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.Use of mTOR inhibitors in human organ transplantation.Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection.Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients.Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation.Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing.CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers.Rapamycin successfully treats post-transplant autoimmune hepatitis.Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions.Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease.On-line solid-phase extraction high-performance liquid chromatography-tandem mass spectrometry for the quantitative analysis of tacrolimus in whole blood hemolyzate.
P2860
Q27697390-E3525C41-35D0-4FF9-93D1-BB53E785B9B1Q35608207-C2026305-9F13-4046-BA40-8AA617A26808Q35827268-1539867C-E962-41A8-9405-759F1A8D6BCAQ35884554-76718334-B1EA-4152-BFBC-7B055182D33BQ35906315-5940FF15-0690-4462-A6ED-BCAEA4500CBAQ35970335-C94D2DD5-A7FB-4645-BC54-E5D6E2354AC6Q36029868-E81BE08C-E92A-47E6-B760-6C97C1519614Q36054093-352EA86F-787A-4B18-ADDB-3159250AFF5EQ36341793-311CD3E7-30BB-471B-B75E-E7F5164F01ABQ36864810-5292DCE3-90CB-497D-9176-D283DD5AE959Q36920414-DBDEF3D1-BBC1-40C2-9C9D-F18070187F8DQ37495852-80FD33B2-6B3D-44BC-9253-C436A96639ECQ38043510-50B93B7A-89D1-4A4A-8587-1E2706D9935EQ38051706-4C32497F-1D08-440E-8889-F711A5E7C2FDQ38209321-D1166022-0CE4-4AF9-B95E-23001262E876Q38828349-F71DF89C-4076-424E-B4A1-811890CE09C8Q42656832-69DC5078-E09A-4399-81D2-F861CF3F907CQ43061556-197A69D3-1C43-4A87-BC40-E8814DDADEA0Q44571955-502F372B-8ACE-435D-B547-F89D95648BA2Q44844484-5D737490-1DA2-4626-AC79-B06E624EA35EQ44989307-99BB764C-D78F-4895-A1DF-8D48B5731F58Q44989320-D4C409D8-4982-4C67-BFC8-6D460E53ABC8Q45016045-683F266D-3325-48F3-A1DB-B09F378413FFQ45078994-BA232F06-9A01-4E1C-BFB4-3B54EF209AFFQ46427150-028F12B4-6867-478B-BCAD-A7FA2399B561Q46485596-C7633266-E84A-4B10-B9A3-C12A8247B9BDQ46703423-0D5D4C79-6EBB-4439-A08E-6FB399E0483CQ48324385-CBD6A775-CFB6-4A8D-90D9-DA615FF3CE83Q53156995-30302511-778E-48A2-A979-FD8362173FB9
P2860
A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A clinical pharmacokinetic stu ...... s to separated administration.
@ast
A clinical pharmacokinetic stu ...... s to separated administration.
@en
A clinical pharmacokinetic stu ...... s to separated administration.
@nl
type
label
A clinical pharmacokinetic stu ...... s to separated administration.
@ast
A clinical pharmacokinetic stu ...... s to separated administration.
@en
A clinical pharmacokinetic stu ...... s to separated administration.
@nl
prefLabel
A clinical pharmacokinetic stu ...... s to separated administration.
@ast
A clinical pharmacokinetic stu ...... s to separated administration.
@en
A clinical pharmacokinetic stu ...... s to separated administration.
@nl
P2093
P1476
A clinical pharmacokinetic stu ...... s to separated administration.
@en
P2093
Albert Fraser
Allan S MacDonald
Kamran Mahalati
P304
P356
10.1097/00007691-200206000-00004
P577
2002-06-01T00:00:00Z